SBRT-LATTICE-PATHY
Impact of Partial Stereotactic Body Radiotherapy in Hypoxic Segments of Large-volume Unresectable Tumors (SBRT-LATTICE-PATHY) - a Prospective Phase II Study.
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Interventie / Behandeling
Interventie / Behandeling
Studietype
Studietype
Inschrijving (Geschat)
Inschrijving
Fase
Fase
- Fase 2
Contacten en locaties
Studiecontact
Studiecontact
- Naam: Principal Investigator
- Telefoonnummer: 551126616722
- E-mail: heloisa.carvalho@hc.fm.usp.br
Studie Locaties
-
-
São Paulo
-
São Paulo, São Paulo, Brazilië, 05403905
- Werving
- Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo - Instituto de Radiologia
-
Contact:
- Principal Investigator
- Telefoonnummer: 551126616722
- E-mail: heloisa.carvalho@hc.fm.usp.br
-
Onderonderzoeker:
- Thiago Brasileiro de Freitas, MD
-
Onderonderzoeker:
- Silvio Thiago Pereira Vasconcelos, MD
-
Onderonderzoeker:
- Caroline Castilhano Sampaio, Medical physicist
-
-
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Beschrijving
Inclusion Criteria:
- age =or> 18 years;
- Eastern Cooperative Oncology Group (ECOG) performance status < 2; benign and malignant tumors for which the use of radiotherapy is well established in the literature;
- tumors =or> 340 cm³ or with a largest diameter =or> 7 cm;
- no indication for any other type of treatment due to lack of proven clinical benefit (surgery, chemotherapy, standard radiotherapy, immunotherapy, targeted therapy, etc.);
- Palliative Prognostic Index (PPI) =or< 2;
- metastatic disease in the central nervous system (CNS), if present, controlled (up to 3 metastases, each up to 1 cm);
- up to 5 extracranial distant metastases (nodal or extranodal) =or< 5 cm; signed Informed Consent Form (ICF).
Exclusion Criteria:
- cases in which tumor volume and/or the patient's clinical condition make adequate immobilization/simulation impossible;
- previous local radiotherapy;
- pregnant patients;
- autoimmune diseases;
- genetic instability syndromes;
- ongoing systemic therapy;
- renal insufficiency that prevents the use of iodinated contrast.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Aantal wapens
Wapens en interventies
Deelnemersgroep / ArmDeelnemersgroep / Arm |
Interventie / BehandelingInterventie / Behandeling |
|---|---|
|
Experimenteel: SBRT-LATTICE-PATHY
1 fraction of 24Gy in intratumoral vertices
|
SBRT-LATTICE-PATHY, a single dose of 24Gy in intratumoral vertices located in hypoxic regions.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Rate of local control at 12 months
Tijdsspanne: From enrollment to the end of treatment at 12 months
|
Percentage of participants achieving local control, defined as absence of local tumor progression assessed by imaging (CT).
|
From enrollment to the end of treatment at 12 months
|
|
Tumor volume shrinkage at 12 months
Tijdsspanne: From enrollment to the end of treatment at 12 months
|
Percentage reduction in gross tumor volume (GTV) measured by CT at 12 months compared to baseline, calculated as [(baseline volume - follow-up volume) / baseline volume] × 100.
|
From enrollment to the end of treatment at 12 months
|
Secundaire uitkomstmaten
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
12-month overall survival rate
Tijdsspanne: 12 months overall survival
|
Percentage of participants alive at 12 months after treatment initiation.
Overall survival is defined as the time from enrollment to death from any cause.
|
12 months overall survival
|
|
12-month progression-free survival rate
Tijdsspanne: 12 months Progression Free Survival
|
Percentage of participants alive and without disease progression at 12 months after treatment initiation.
Progression is assessed by CT imaging.
Time is measured from enrollment to the first documented disease progression or death from any cause, whichever occurs first.
|
12 months Progression Free Survival
|
|
Rate of acute adverse events assessed by CTCAE v 5.0
Tijdsspanne: 15 days, 1 month and 3 months after treatment initiation
|
Incidence and severity of acute adverse events assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (NCI CTCAE v5.0).
Reported as the percentage of participants experiencing grade ≥1 adverse events.
Assessed at 15 days, 1 month, and 3 months after treatment initiation.
|
15 days, 1 month and 3 months after treatment initiation
|
|
Rate of late adverse events assessed by CTCAE v5.0
Tijdsspanne: 6, 9 and 12 months after treatment completion
|
Incidence and severity of late adverse events assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (NCI CTCAE v5.0).
Reported as the percentage of participants experiencing grade ≥1 adverse events.
Assessed at 6, 9, and 12 months after treatment completion.
|
6, 9 and 12 months after treatment completion
|
|
Mean EORTC QLC-C30 Global Health Status / Quality of Life Score)
Tijdsspanne: Impact in quality of life in 1, 3, 6, 9 and 12 months after treatment completion
|
Quality of life assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30).
The Global Health Status/QoL subscale is scored from 0 to 100, where higher scores indicate better quality of life.
Assessed at 1, 3, 6, 9, and 12 months after treatment.
|
Impact in quality of life in 1, 3, 6, 9 and 12 months after treatment completion
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Onderzoekers
Onderzoekers
- Hoofdonderzoeker: Heloisa de Andrade Carvalho, MD, PhD, University of Sao Paulo
Publicaties en nuttige links
Algemene publicaties
- Yan W, Khan MK, Wu X, Simone CB 2nd, Fan J, Gressen E, Zhang X, Limoli CL, Bahig H, Tubin S, Mourad WF. Spatially fractionated radiation therapy: History, present and the future. Clin Transl Radiat Oncol. 2019 Oct 22;20:30-38. doi: 10.1016/j.ctro.2019.10.004. eCollection 2020 Jan. No abstract available.
- Duriseti S, Kavanaugh JA, Szymanski J, Huang Y, Basarabescu F, Chaudhuri A, Henke L, Samson P, Lin A, Robinson C, Spraker MB. LITE SABR M1: A phase I trial of Lattice stereotactic body radiotherapy for large tumors. Radiother Oncol. 2022 Feb;167:317-322. doi: 10.1016/j.radonc.2021.11.023. Epub 2021 Dec 4.
- Korpics MC, Onderdonk BE, Dadey RE, Hara JH, Karapetyan L, Zha Y, Karrison TG, Olson AC, Fleming GF, Weichselbaum RR, Bao R, Chmura SJ, Luke JJ. Partial tumor irradiation plus pembrolizumab in treating large advanced solid tumor metastases. J Clin Invest. 2023 May 15;133(10):e162260. doi: 10.1172/JCI162260.
- Amendola BE, Perez NC, Wu X, Blanco Suarez JM, Lu JJ, Amendola M. Improved outcome of treating locally advanced lung cancer with the use of Lattice Radiotherapy (LRT): A case report. Clin Transl Radiat Oncol. 2018 Jan 12;9:68-71. doi: 10.1016/j.ctro.2018.01.003. eCollection 2018 Feb.
- Ikeda T, Sun L, Tsuruoka N, Ishigaki Y, Yoshitomi Y, Yoshitake Y, Yonekura H. Hypoxia down-regulates sFlt-1 (sVEGFR-1) expression in human microvascular endothelial cells by a mechanism involving mRNA alternative processing. Biochem J. 2011 Jun 1;436(2):399-407. doi: 10.1042/BJ20101490.
- Tubin S, Popper HH, Brcic L. Novel stereotactic body radiation therapy (SBRT)-based partial tumor irradiation targeting hypoxic segment of bulky tumors (SBRT-PATHY): improvement of the radiotherapy outcome by exploiting the bystander and abscopal effects. Radiat Oncol. 2019 Jan 29;14(1):21. doi: 10.1186/s13014-019-1227-y.
- Tubin S, Ahmed MM, Gupta S. Radiation and hypoxia-induced non-targeted effects in normoxic and hypoxic conditions in human lung cancer cells. Int J Radiat Biol. 2018 Mar;94(3):199-211. doi: 10.1080/09553002.2018.1422085. Epub 2018 Jan 12.
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Studie start
Primaire voltooiing (Geschat)
Primaire voltooiing
Studie voltooiing (Geschat)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
Andere studie-ID-nummers
- 86859225.3.0000.0068
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
IPD-tijdsbestek voor delen
IPD-toegangscriteria voor delen
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
- ICF
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .